|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2627-2632.
Prepublished online as a Blood First Edition Paper on July 5, 2005; DOI 10.1182/blood-2004-12-4602.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Norihiro Nishimoto,
Yuzuru Kanakura,
Katsuyuki Aozasa,
Takeshi Johkoh,
Minoru Nakamura,
Shuji Nakano,
Nobuaki Nakano,
Yasuo Ikeda,
Takeshi Sasaki,
Kiyoshi Nishioka,
Masamichi Hara,
Hirokuni Taguchi,
Yukihiko Kimura,
Yoshiro Kato,
Hideki Asaoku,
Shunichi Kumagai,
Fumio Kodama,
Hideko Nakahara,
Keisuke Hagihara,
Kazuyuki Yoshizaki, and
Tadamitsu Kishimoto
From Osaka University, Osaka; Kyowakai Hospital, Osaka; Kyushu University, Fukuoka; Keio University, Tokyo; Tohoku University, Miyagi; Tokyo Medical and Dental University, Tokyo; Ehime Prefectural Central Hospital, Ehime; Kochi Medical School, Kochi; Tokyo Medical University, Tokyo; Aichi Medical University, Aichi; Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima; Kobe University, Hyogo; and Kanagawa Cancer Center, Kanagawa, Japan; as the Japanese MRA study group on MCD.
Multicentric Castleman disease (MCD) is an atypical lymphoproliferative disorder characterized by systemic lymphadenopathy and constitutional inflammatory symptoms. Dysregulated overproduction of interleukin-6 is responsible for the clinical abnormalities. This multicenter prospective study was undertaken to evaluate the safety and efficacy of a humanized anti–human interleukin-6 (IL-6) receptor monoclonal antibody (MRA) in patients with MCD. We report here results of the first 60 weeks of the study enrolling 28 patients. The initial dosing period consisted of 8 infusions of 8 mg/kg MRA administered biweekly. Adjustments in the dose and treatment interval were allowed for each patient in an extension phase after 16 weeks. Within 16 weeks, treatment with MRA consistently alleviated lymphadenopathy and all the inflammatory parameters. Hemoglobin, albumin, and total cholesterol levels, high-density lipoprotein cholesterol values, and body mass index all increased significantly. In addition, fatigue diminished. Chronic inflammatory symptoms were successfully managed over 60 weeks. In 8 (28.6%) patients, the MRA dose was decreased or the treatment interval was extended without exacerbation. Eleven (73.3%) of 15 patients who had received oral corticosteroids before study entry were able to do well on a reduced corticosteroid dose. Most adverse events were mild to moderate in severity. MRA was tolerated well and significantly alleviated chronic inflammatory symptoms and wasting in patients with MCD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Nishikawa, K. Hagihara, S. Serada, T. Isobe, A. Matsumura, J. Song, T. Tanaka, I. Kawase, T. Naka, and K. Yoshizaki
Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1{alpha} Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression
J. Immunol.,
March 1, 2008;
180(5):
3492 - 3501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Rabe, A. Chalaris, U. May, G. H. Waetzig, D. Seegert, A. S. Williams, S. A. Jones, S. Rose-John, and J. Scheller
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation
Blood,
February 1, 2008;
111(3):
1021 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ahmed, J. A. Tschen, P. R. Cohen, M. H. Zaki, P. L. Rady, S. K. Tyring, R. E. Corringham, and R. Kurzrock
Cutaneous castleman's disease responds to anti interleukin-6 treatment
Mol. Cancer Ther.,
September 1, 2007;
6(9):
2386 - 2390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, N. Murata, D. van der Heijde, and T. Kishimoto
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Ann Rheum Dis,
September 1, 2007;
66(9):
1162 - 1167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kawabata, N. Tomosugi, J. Kanda, Y. Tanaka, K. Yoshizaki, and T. Uchiyama
Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease
Haematologica,
June 1, 2007;
92(6):
857 - 858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Izumi-Nagai, N. Nagai, Y. Ozawa, M. Mihara, Y. Ohsugi, T. Kurihara, T. Koto, S. Satofuka, M. Inoue, K. Tsubota, et al.
Interleukin-6 Receptor-Mediated Activation of Signal Transducer and Activator of Transcription-3 (STAT3) Promotes Choroidal Neovascularization
Am. J. Pathol.,
June 1, 2007;
170(6):
2149 - 2158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow
Mechanisms of Cancer-Related Fatigue
Oncologist,
May 1, 2007;
12(suppl_1):
22 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-F. Qi, J. X. Zhou, C. H. Lee, Z. Naghashfar, S. Xiang, A. L. Kovalchuk, T. N. Fredrickson, J. W. Hartley, D. C. Roopenian, W. F. Davidson, et al.
Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late-Stage Differentiation of Normal B Cells
Cancer Res.,
March 15, 2007;
67(6):
2439 - 2447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Metz, M. Wiesinger, M. Vogt, H. Lauks, G. Schmalzing, P. C. Heinrich, and G. Muller-Newen
Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: FUSED RECEPTOR DOMAINS ACT AS HIGH AFFINITY CYTOKINE-BINDING PROTEINS
J. Biol. Chem.,
January 12, 2007;
282(2):
1238 - 1248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rose-John, J. Scheller, G. Elson, and S. A. Jones
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer
J. Leukoc. Biol.,
August 1, 2006;
80(2):
227 - 236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci
Interleukin-6 in aging and chronic disease: a magnificent pathway.
J. Gerontol. A Biol. Sci. Med. Sci.,
June 1, 2006;
61(6):
575 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
